Adult-Onset Type 1 Diabetes: Current Understanding and Challenges

R David Leslie, Carmella Evans-Molina, Jacquelyn Freund-Brown, Raffaella Buzzetti, Dana Dabelea, Kathleen M Gillespie, Robin Goland, Angus G Jones, Mark Kacher, Lawrence S Phillips, Olov Rolandsson, Jana L Wardian, Jessica L Dunne, R David Leslie, Carmella Evans-Molina, Jacquelyn Freund-Brown, Raffaella Buzzetti, Dana Dabelea, Kathleen M Gillespie, Robin Goland, Angus G Jones, Mark Kacher, Lawrence S Phillips, Olov Rolandsson, Jana L Wardian, Jessica L Dunne

Abstract

Recent epidemiological data have shown that more than half of all new cases of type 1 diabetes occur in adults. Key genetic, immune, and metabolic differences exist between adult- and childhood-onset type 1 diabetes, many of which are not well understood. A substantial risk of misclassification of diabetes type can result. Notably, some adults with type 1 diabetes may not require insulin at diagnosis, their clinical disease can masquerade as type 2 diabetes, and the consequent misclassification may result in inappropriate treatment. In response to this important issue, JDRF convened a workshop of international experts in November 2019. Here, we summarize the current understanding and unanswered questions in the field based on those discussions, highlighting epidemiology and immunogenetic and metabolic characteristics of adult-onset type 1 diabetes as well as disease-associated comorbidities and psychosocial challenges. In adult-onset, as compared with childhood-onset, type 1 diabetes, HLA-associated risk is lower, with more protective genotypes and lower genetic risk scores; multiple diabetes-associated autoantibodies are decreased, though GADA remains dominant. Before diagnosis, those with autoantibodies progress more slowly, and at diagnosis, serum C-peptide is higher in adults than children, with ketoacidosis being less frequent. Tools to distinguish types of diabetes are discussed, including body phenotype, clinical course, family history, autoantibodies, comorbidities, and C-peptide. By providing this perspective, we aim to improve the management of adults presenting with type 1 diabetes.

© 2021 by the American Diabetes Association.

Figures

Figure 1
Figure 1
Proposed roadmap to better understand, diagnose, and care for adults with type 1 diabetes (T1D). Created in BioRender (BioRender.com).

References

    1. Muñoz C, Floreen A, Garey C, et al. . Misdiagnosis and diabetic ketoacidosis at diagnosis of type 1 diabetes: patient and caregiver perspe ctives. Clin Diabetes 2019;37:276–281
    1. Thomas NJ, Lynam AL, Hill AV, et al. . Type 1 diabetes defined by severe insulin deficiency occurs after 30 years of age and is commonly treated as type 2 diabetes. Diabetologia 2019;62: 1167–1172
    1. Thunander M, Petersson C, Jonzon K, et al. . Incidence of type 1 and type 2 diabetes in adults and children in Kronoberg, Sweden. Diabetes Res Clin Pract 2008;82:247–255
    1. Rogers MAM, Kim C, Banerjee T, Lee JM. Fluctuations in the incidence of type 1 diabetes in the United States from 2001 to 2015: a longitudinal study. BMC Med 2017;15:199.
    1. Weng J, Zhou Z, Guo L, et al. .; T1D China Study Group . Incidence of type 1 diabetes in China, 2010-13: population based study. BMJ 2018;360:j5295.
    1. Thomas NJ, Jones SE, Weedon MN, Shields BM, Oram RA, Hattersley AT. Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank. Lancet Diabetes Endocrinol 2018;6:122–129
    1. Diaz-Valencia PA, Bougnères P, Valleron AJ. Global epidemiology of type 1 diabetes in young adults and adults: a systematic review. BMC Public Health 2015;15:255.
    1. Gorham ED, Barrett-Connor E, Highfill-McRoy RM, et al. . Incidence of insulin-requiring diabetes in the US military. Diabetologia 2009;52:2087–2091
    1. Hawa MI, Kolb H, Schloot N, et al. .; Action LADA Consortium . Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7. Diabetes Care 2013;36:908–913
    1. Xiang Y, Huang G, Zhu Y, et al. .; China National Diabetes and Metabolic Disorders Study Group . Identification of autoimmune type 1 diabetes and multiple organ-specific autoantibodies in adult-onset non-insulin-requiring diabetes in China: a population-based multicentre nationwide survey. Diabetes Obes Metab 2019;21:893–902
    1. Ziegler AG, Rewers M, Simell O, et al. . Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013;309:2473–2479
    1. Wherrett DK, Chiang JL, Delamater AM, et al. .; Type 1 Diabetes TrialNet Study Group . Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report. Diabetes Care 2015;38:1975–1985
    1. Rolandsson O, Hampe CS, Sharp SJ, et al. . Autoimmunity plays a role in the onset of diabetes after 40 years of age. Diabetologia 2020;63:266–277
    1. Mishra R, Åkerlund M, Cousminer DL, et al. . Genetic discrimination between LADA and childhood-onset type 1 diabetes within the MHC. Diabetes Care 2020;43:418–425
    1. Zhu M, Xu K, Chen Y, et al. . Identification of novel T1D risk loci and their association with age and islet function at diagnosis in autoantibody-positive T1D individuals: based on a two-stage genome-wide association study. Diabetes Care 2019;42:1414–1421
    1. Buzzetti R, Di Pietro S, Giaccari A, et al. .; Non Insulin Requiring Autoimmune Diabetes Study Group . High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care 2007;30:932–938
    1. Yasui J, Kawasaki E, Tanaka S, et al. .; Japan Diabetes Society Committee on Type 1 Diabetes Mellitus Research . Clinical and genetic characteristics of non-insulin-requiring glutamic acid decarboxylase (GAD) autoantibody-positive diabetes: a nationwide survey in Japan. PLoS One 2016;11:e0155643.
    1. Zhou Z, Xiang Y, Ji L, et al. .; LADA China Study Group . Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study. Diabetes 2013;62:543–550
    1. Howson JM, Rosinger S, Smyth DJ, Boehm BO; ADBW-END Study Group . Genetic analysis of adult-onset autoimmune diabetes. Diabetes 2011;60:2645–2653
    1. Battaglia M, Ahmed S, Anderson MS, et al. . Introducing the endotype concept to address the challenge of disease heterogeneity in type 1 diabetes. Diabetes Care 2020;43:5–12
    1. Redondo MJ, Yu L, Hawa M, et al. . Heterogeneity of type I diabetes: analysis of monozygotic twins in Great Britain and the United States. Diabetologia 2001;44:354–362
    1. Lynam A, McDonald T, Hill A, et al. . Development and validation of multivariable clinical diagnostic models to identify type 1 diabetes requiring rapid insulin therapy in adults aged 18-50 years. BMJ Open 2019;9:e031586
    1. Cousminer DL, Ahlqvist E, Mishra R, et al. .; Bone Mineral Density in Childhood Study . First genome-wide association study of latent autoimmune diabetes in adults reveals novel insights linking immune and metabolic diabetes. Diabetes Care 2018;41:2396–2403
    1. Zampetti S, Capizzi M, Spoletini M, et al. .; NIRAD Study Group . GADA titer-related risk for organ-specific autoimmunity in LADA subjects subdivided according to gender (NIRAD study 6). J Clin Endocrinol Metab 2012;97:3759–3765
    1. Balcha SA, Demisse AG, Mishra R, et al. . Type 1 diabetes in Africa: an immunogenetic study in the Amhara of North-West Ethiopia. Diabetologia 2020;63:2158–2168
    1. Jacobsen LM, Bocchino L, Evans-Molina C, et al. . The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening. Diabetologia 2020;63:588–596
    1. Long AE, Wilson IV, Becker DJ, et al. . Characteristics of slow progression to diabetes in multiple islet autoantibody-positive individuals from five longitudinal cohorts: the SNAIL study. Diabetologia 2018;61:1484–1490
    1. Hanna SJ, Powell WE, Long AE, et al. . Slow progressors to type 1 diabetes lose islet autoantibodies over time, have few islet antigen-specific CD8+ T cells and exhibit a distinct CD95hi B cell phenotype. Diabetologia 2020;63:1174–1185
    1. Schloot NC, Pham MN, Hawa MI, et al. .; Action LADA Group . Inverse relationship between organ-specific autoantibodies and systemic immune mediators in type 1 diabetes and type 2 diabetes: Action LADA 11. Diabetes Care 2016;39:1932–1939
    1. Brooks-Worrell BM, Palmer JP. Setting the stage for islet autoimmunity in type 2 diabetes: obesity-associated chronic systemic inflammation and endoplasmic reticulum (ER) stress. Diabetes Care 2019;42:2338–2346
    1. Campbell-Thompson M, Fu A, Kaddis JS, et al. . Insulitis and β-cell mass in the natural history of type 1 diabetes. Diabetes 2016;65:719–731
    1. Leete P, Willcox A, Krogvold L, et al. . Differential insulitic profiles determine the extent of β-cell destruction and the age at onset of type 1 diabetes. Diabetes 2016;65:1362–1369
    1. Fleiner HF, Bjøro T, Midthjell K, Grill V, Åsvold BO. Prevalence of thyroid dysfunction in autoimmune and type 2 diabetes: the population-based HUNT study in Norway. J Clin Endocrinol Metab 2016;101:669–677
    1. Greenbaum CJ, Beam CA, Boulware D, et al. .; Type 1 Diabetes TrialNet Study Group . Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 2012;61:2066–2073
    1. Gong S, Wu C, Zhong T, et al. . Complicated curve association of body weight at diagnosis with C-peptide in children and adults with new-onset type 1 diabetes. Diabetes Metab Res Rev 2020;36:e3285.
    1. Hao W, Gitelman S, DiMeglio LA, Boulware D; Type 1 Diabetes TrialNet Study Group . Fall in c-peptide during first 4 years from diagnosis of type 1 diabetes: variable relation to age, HbA1c, and insulin dose. Diabetes Care 2016;39:1664–1670
    1. Foster NC, Beck RW, Miller KM, et al. . State of type 1 diabetes management and outcomes from the T1D exchange in 2016-2018. Diabetes Technol Ther 2019;21:66–72
    1. Rickels MR, Evans-Molina C, Bahnson HT, et al. .; T1D Exchange β-Cell Function Study Group . High residual C-peptide likely contributes to glycemic control in type 1 diabetes. J Clin Invest 2020;130:1850–1862
    1. Davis AK, DuBose SN, Haller MJ, et al. .; T1D Exchange Clinic Network . Prevalence of detectable C-peptide according to age at diagnosis and duration of type 1 diabetes. Diabetes Care 2015;38:476–481
    1. Andersen CD, Bennet L, Nyström L, et al. . Worse glycaemic control in LADA patients than in those with type 2 diabetes, despite a longer time on insulin therapy. Diabetologia 2013;56:252–258
    1. Sims EK, Chaudhry Z, Watkins R, et al. . Elevations in the fasting serum proinsulin-to-C-peptide ratio precede the onset of type 1 diabetes. Diabetes Care 2016;39:1519–1526
    1. Sims EK, Bahnson HT, Nyalwidhe J, et al. .; T1D Exchange Residual C-Peptide Study Group . Proinsulin secretion is a persistent feature of type 1 diabetes. Diabetes Care 2019;42:258–264
    1. Shields BM, Peters JL, Cooper C, et al. . Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature. BMJ Open 2015;5:e009088
    1. Ahlqvist E, Storm P, Käräjämäki A, et al. . Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 2018;6:361–369
    1. Hawa MI, Thivolet C, Mauricio D, et al. .; Action LADA Group . Metabolic syndrome and autoimmune diabetes: action LADA 3. Diabetes Care 2009;32:160–164
    1. Jones AG, McDonald TJ, Shields BM, Hagopian W, Hattersley AT. Latent autoimmune diabetes of adults (LADA) is likely to represent a mixed population of autoimmune (type 1) and nonautoimmune (type 2) diabetes. Diabetes Care 2021. dc202834.
    1. Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med 2013;30:803–817
    1. Berger B, Stenström G, Sundkvist G. Random C-peptide in the classification of diabetes. Scand J Clin Lab Invest 2000;60:687–693
    1. Hope SV, Knight BA, Shields BM, Hattersley AT, McDonald TJ, Jones AG. Random non-fasting C-peptide: bringing robust assessment of endogenous insulin secretion to the clinic. Diabet Med 2016;33:1554–1558
    1. Buzzetti R, Tuomi T, Mauricio D, et al. . Management of latent autoimmune diabetes in adults: a consensus statement from an international expert panel. Diabetes 2020;69:2037–2047
    1. Danne T, Garg S, Peters AL, et al. . International consensus on risk management of diabetic keto-acidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care 2019;42:1147–1154
    1. Dabelea D, Rewers A, Stafford JM, et al. .; SEARCH for Diabetes in Youth Study Group . Trends in the prevalence of ketoacidosis at diabetes diagnosis: the SEARCH for diabetes in youth study. Pediatrics 2014;133:e938–e945
    1. Rewers A. Acute metabolic complications in diabetes. In Diabetes in America. 3rd ed. Bethesda, MD, National Institute of Diabetes and Digestive and Kidney Diseases, 2018; pp. 1–19
    1. Umpierrez GE, Kitabchi AE. Diabetic ketoac-idosis: risk factors and management strategies. Treat Endocrinol 2003;2:95–108
    1. Randall L, Begovic J, Hudson M, et al. . Recurrent diabetic ketoacidosis in inner-city minority patients: behavioral, socioeconomic, and psychosocial factors. Diabetes Care 2011;34:1891–1896
    1. Duca LM, Reboussin BA, Pihoker C, et al. . Diabetic ketoacidosis at diagnosis of type 1 diabetes and glycemic control over time: the SEARCH for diabetes in youth study. Pediatr Diabetes 2019;20:172–179
    1. Martyn-Nemeth P, Schwarz Farabi S, Mihailescu D, Nemeth J, Quinn L. Fear of hypoglycemia in adults with type 1 diabetes: impact of therapeutic advances and strategies for prevention – a review. J Diabetes Complications 2016;30:167–177
    1. Engler R, Routh TL, Lucisano JY. Adoption barriers for continuous glucose monitoring and their potential reduction with a fully implanted system: results from patient preference surveys. Clin Diabetes 2018;36:50–58
    1. Isomaa B, Almgren P, Henricsson M, et al. . Chronic complications in patients with slowly progressing autoimmune type 1 diabetes (LADA). Diabetes Care 1999;22:1347–1353
    1. Maddaloni E, Coleman RL, Agbaje O, Buzzetti R, Holman RR. Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86). Lancet Diabetes Endocrinol 2020;8:206–215
    1. Maddaloni E, Coleman RL, Pozzilli P, Holman RR. Long-term risk of cardiovascular disease in individuals with latent autoimmune diabetes in adults (UKPDS 85). Diabetes Obes Metab 2019;21:2115–2122
    1. Tuomi T, Carlsson A, Li H, et al. . Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 1999;48:150–157
    1. Robinson ME, Simard M, Larocque I, Shah J, Nakhla M, Rahme E. Risk of psychiatric disorders and suicide attempts in emerging adults with diabetes. Diabetes Care 2020;43:484–486
    1. Yi JP, Vitaliano PP, Smith RE, Yi JC, Weinger K. The role of resilience on psychological adjustment and physical health in patients with diabetes. Br J Health Psychol 2008;13:311–325
    1. Trief PM, Sandberg JG, Dimmock JA, Forken PJ, Weinstock RS. Personal and relationship challenges of adults with type 1 diabetes: a qualitative focus group study. Diabetes Care 2013;36:2483–2488
    1. Fisher L, Polonsky WH, Hessler DM, et al. . Understanding the sources of diabetes distress in adults with type 1 diabetes. J Diabetes Complications 2015;29:572–577
    1. Hilliard ME, Yi-Frazier JP, Hessler D, Butler AM, Anderson BJ, Jaser S. Stress and A1c among people with diabetes across the lifespan. Curr Diab Rep 2016;16:67.
    1. Lloyd CE, Dyer PH, Lancashire RJ, Harris T, Daniels JE, Barnett AH. Association between stress and glycemic control in adults with type 1 (insulin-dependent) diabetes. Diabetes Care 1999;22:1278–1283

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe